Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy

Highlights • rLaSota/IL2 has an antitumor potency but is not a pathogenic for man and poultry. • rLaSota/IL2 enhanced the anti-tumor effects and improved the surveillance of tumor-bearing mice compared with rLasota. • Tumor-specific CTL responses are significantly stimulated after rLaSota/IL2-treate...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Immunology letters 2014-05, Vol.159 (1), p.36-46
Hauptverfasser:	Bai, Fuliang, Niu, Zeshan, Tian, Hui, Li, Siming, Lv, Zheng, Zhang, Tianyuan, Ren, Guiping, Li, Deshan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptive Immunity Allergy and Immunology Animals Cancer therapy Carcinoma, Hepatocellular - immunology Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Cell Line, Tumor Cell Proliferation Gene Expression Genetic Engineering Humans IL2 Immunologic Memory Immunotherapy Immunotherapy - methods Interleukin-2 - biosynthesis Interleukin-2 - genetics Interleukin-2 - immunology Liver Neoplasms, Experimental - immunology Liver Neoplasms, Experimental - mortality Liver Neoplasms, Experimental - pathology Liver Neoplasms, Experimental - therapy Melanoma, Experimental - immunology Melanoma, Experimental - mortality Melanoma, Experimental - pathology Melanoma, Experimental - therapy Mice NDV Newcastle disease virus - genetics Oncolytic therapy Oncolytic Virotherapy - methods rLaSota/IL2 Skin Neoplasms - immunology Skin Neoplasms - mortality Skin Neoplasms - pathology Skin Neoplasms - therapy Survival Analysis T-Lymphocytes, Cytotoxic - immunology T-Lymphocytes, Cytotoxic - pathology T-Lymphocytes, Regulatory - immunology T-Lymphocytes, Regulatory - pathology Tumor Burden
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • rLaSota/IL2 has an antitumor potency but is not a pathogenic for man and poultry. • rLaSota/IL2 enhanced the anti-tumor effects and improved the surveillance of tumor-bearing mice compared with rLasota. • Tumor-specific CTL responses are significantly stimulated after rLaSota/IL2-treated in tumor-bearing mice. • CD4+ and CD8+ T cells proliferation and expression of MHC II are increased after treatment with rLaSota/IL2.
ISSN:	0165-2478 1879-0542
DOI:	10.1016/j.imlet.2014.02.009